1. Academic Validation
  2. Optimization of 1,2,5-thiadiazole carbamates as potent and selective ABHD6 inhibitors

Optimization of 1,2,5-thiadiazole carbamates as potent and selective ABHD6 inhibitors

  • ChemMedChem. 2015 Feb;10(2):253-65. doi: 10.1002/cmdc.201402453.
Jayendra Z Patel 1 Tapio J Nevalainen Juha R Savinainen Yahaya Adams Tuomo Laitinen Robert S Runyon Miia Vaara Stephen Ahenkorah Agnieszka A Kaczor Dina Navia-Paldanius Mikko Gynther Niina Aaltonen Amit A Joharapurkar Mukul R Jain Abigail S Haka Frederick R Maxfield Jarmo T Laitinen Teija Parkkari
Affiliations

Affiliation

  • 1 School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio (Finland). jayendra.patel@uef.fi.
Abstract

At present, inhibitors of α/β-hydrolase domain 6 (ABHD6) are viewed as a promising approach to treat inflammation and metabolic disorders. This article describes the development of 1,2,5-thiadiazole carbamates as ABHD6 inhibitors. Altogether, 34 compounds were synthesized, and their inhibitory activity was tested using lysates of HEK293 cells transiently expressing human ABHD6 (hABHD6). Among the compound series, 4-morpholino-1,2,5-thiadiazol-3-yl cyclooctyl(methyl)carbamate (JZP-430) potently and irreversibly inhibited hABHD6 (IC50 =44 nM) and showed ∼230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid Lipase (LAL), the main off-targets of related compounds. Additionally, activity-based protein profiling indicated that JZP-430 displays good selectivity among the serine hydrolases of the mouse brain membrane proteome. JZP-430 has been identified as a highly selective, irreversible inhibitor of hABHD6, which may provide a novel approach in the treatment of obesity and type II diabetes.

Keywords

1,2,5-thiadiazole carbamates; 2-arachidonoylglycerol; ABHD6; cannabinoids; homology modeling; receptors.

Figures
Products